NEU 0.06% $15.56 neuren pharmaceuticals limited

NNZ-2566 (oral)- Rett Syndrome Phase III 2018 20.0% $557 60.0%...

  1. 5,796 Posts.
    lightbulb Created with Sketch. 736
    NNZ-2566 (oral)- Rett Syndrome Phase III 2018 20.0% $557 60.0% $294 $0.17

    NNZ-2566 (oral)- Fragile X Syndrome Phase II 2019 10.0% $700 29% $180 $0.10


    Can we please cut the crap here. Such pathetic valuations.

    Rett's Market share 20% = $557m

    Fragile X market Share 10% =$700m

    So whose got the other 80% and 90% ning nongs???

    Do your valuations properly. These companies don't want to go out an a limb and do it properly.

    Can someone recalibrate the valuations from these two alone having 100% of the market share?
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$15.56
Change
-0.010(0.06%)
Mkt cap ! $1.988B
Open High Low Value Volume
$15.40 $16.06 $15.36 $9.126M 583.1K

Buyers (Bids)

No. Vol. Price($)
1 255 $15.56
 

Sellers (Offers)

Price($) Vol. No.
$15.70 1442 2
View Market Depth
Last trade - 16.10pm 19/08/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.